Editor's Corner


FierceBiotech caught up with Bart Bergstein, the managing partner of Forbion Capital Partners, earlier this week to discuss the latest trends he's seeing in venture capital. Forbion operates from offices near Amsterdam and recently spun out of ABN AMRO with a new €200 million fund that will be betting heavily on drug development over the next three years. While Bergstein offers some key insights into the European market, he's also an accomplished player on both sides of the Atlantic. His portfolio includes the lead role in a series B €40 million fundraising for Santaris Pharma, the €22 million series A investment in Amsterdam Molecular Therapeutics and the €13 million series B round of PanGenetics. You can learn more about what Bergstein is seeing--and doing--in our Friday Feature below.

We'll be rolling out a regular series of interviews and trend stories over the coming year. Late next month we'll also offer up our first webinar of the year on economic development. This is all part of our plan to continue to expand our coverage of biotechnology to bring you the kind of insight biotech insiders need to do their jobs.

As for Monday, it's Martin Luther King Jr. Day, and we're taking off for the holiday. We'll see you again on Tuesday, January 16th. - John Carroll

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.